Literature DB >> 12085239

Enhanced engraftment of EPO-transduced human bone marrow stromal cells transplanted in a 3D matrix in non-conditioned NOD/SCID mice.

A Daga1, A Muraglia, R Quarto, R Cancedda, G Corte.   

Abstract

Intravenous infusion of bone marrow stromal cells (BMSCs) has been proposed as a means to support hematopoiesis in bone marrow transplantation or as a vehicle for gene therapy. However, it seems that this route of injection leads to engraftment of a small proportion of BMSCs, possibly because they are unable to cross the endothelial barrier. We have transplanted human BMSCs, ex vivo expanded and transduced with a retrovirus encoding the human erythropoietin gene, either intravenously or subcutaneously with or without a tridimensional scaffold in non-conditioned NOD/SCID mice. Efficiency of engraftment was evaluated monitoring the hematocrit levels. Systemic infusion never significantly increased hematocrit levels, whereas subcutaneous transplantation of the same number of cells induced an important increase of the hematocrit (approximately 70%) for at least 2 months. A substantial increase in the length of the response was observed when cells were subcutaneously transplanted in a tridimensional scaffold. To determine whether the transient effect was due to cell loss or to reduction in expression, the cells implanted into a tridimensional scaffold were recovered, expanded in vitro, and re-implanted in a new group of mice. Again the hematocrit levels rose 2 weeks after transplantation ( approximately 70%). These results demonstrate that ex vivo expanded human BMSCs are not quantitatively transplantable by systemic infusion in non-conditioned recipients, whereas the local implantation into a tridimensional scaffold allows long-term engraftment and efficient expression of a foreign gene.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12085239     DOI: 10.1038/sj.gt.3301727

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  7 in total

1.  In vivo bone formation by progeny of human embryonic stem cells.

Authors:  Sergei A Kuznetsov; Natasha Cherman; Pamela Gehron Robey
Journal:  Stem Cells Dev       Date:  2010-09-14       Impact factor: 3.272

2.  Transplanted Umbilical Cord Mesenchymal Stem Cells Modify the In Vivo Microenvironment Enhancing Angiogenesis and Leading to Bone Regeneration.

Authors:  Maria Rosa Todeschi; Rania El Backly; Chiara Capelli; Antonio Daga; Eugenio Patrone; Martino Introna; Ranieri Cancedda; Maddalena Mastrogiacomo
Journal:  Stem Cells Dev       Date:  2015-03-18       Impact factor: 3.272

3.  Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants.

Authors:  Anabel S de la Garza-Rodea; Marieke C Verweij; Hester Boersma; Ietje van der Velde-van Dijke; Antoine A F de Vries; Rob C Hoeben; Dirk W van Bekkum; Emmanuel J H J Wiertz; Shoshan Knaän-Shanzer
Journal:  PLoS One       Date:  2011-01-06       Impact factor: 3.240

4.  Erythropoietin gene-enhanced marrow mesenchymal stromal cells decrease cisplatin-induced kidney injury and improve survival of allogeneic mice.

Authors:  Nicoletta Eliopoulos; Jing Zhao; Kathy Forner; Elena Birman; Yoon Kow Young; Manaf Bouchentouf
Journal:  Mol Ther       Date:  2011-08-16       Impact factor: 11.454

Review 5.  Erythropoietin in Optic Neuropathies: Current Future Strategies for Optic Nerve Protection and Repair.

Authors:  Yi-Fen Lai; Ting-Yi Lin; Pin-Kuan Ho; Yi-Hao Chen; Yu-Chuan Huang; Da-Wen Lu
Journal:  Int J Mol Sci       Date:  2022-06-27       Impact factor: 6.208

6.  A dedicated automated injection system for dynamic contrast-enhanced MRI experiments in mice.

Authors:  Jan Sedlacik; Adrianne Myers; Ralf B Loeffler; Regan F Williams; Andrew M Davidoff; Claudia M Hillenbrand
Journal:  J Magn Reson Imaging       Date:  2012-09-21       Impact factor: 4.813

Review 7.  Revisiting the role of erythropoietin for treatment of ocular disorders.

Authors:  S L Shirley Ding; S N Leow; R Munisvaradass; E H Koh; M L C Bastion; K Y Then; S Kumar; P L Mok
Journal:  Eye (Lond)       Date:  2016-06-10       Impact factor: 3.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.